Photo of Howard L Kaufman,  MD

Howard L Kaufman, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000


HLKaufman@mgh.harvard.edu

Howard L Kaufman, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Lecturer, Surgery, Harvard Medical School
  • Assistant in Surgery, Surgery, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Kaufman's research has focused on the development of oncolytic viruses and immunotherapy for the treatment of melanoma and other types of cutaneous malignancies. His lab has contributed to understanding how viruses induce immunogenic cell death and initiate host anti-tumor immunity. He led the first randomized phase III clinical trial of an oncolytic herpes simplex type 1 (HSV-1) virus encoding GM-CSF in patients with advanced melanoma, which resulted in FDA approval of the first oncolytic virus in cancer. He also helped establish the role of anti-PD-L1 treatment for patients with advanced Merkel cell carcinoma. He continues to focus on how to integrate oncolytic viruses into combination immunotherapy regimens to enhance systemic immunity and improve therapeutic responses in patients with cancer.

Publications

Powered by Harvard Catalyst
  • Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am 2019; 28:419-430. PubMed
  • Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, ”¶hrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 2019; 7:145. PubMed
  • Ugolini H, Bryan J, Hennessy M, Kaufman HL, D'Angelo S. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. 2019; 23:E1-E9. PubMed
  • Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer 2019; 7:26. PubMed
  • Bommareddy PK, Rabkin SD, Kaufman HL. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology 2019; 8:e1571390. PubMed
  • Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods 2019. PubMed
  • Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 2019; 8:1591875. PubMed
  • Kaufman HL, Schwartz LH, William WN, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2018; 144:2245-2261. PubMed
  • Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018; 18:498-513. PubMed
  • Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018. JAMA Oncol 2018; 4:857-858. PubMed
  • Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest 2019; 128:1258-1260. PubMed
  • Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J Immunother Cancer 2018; 6:23. PubMed
  • Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncol 2018; 14:255-266. PubMed
Hide